Tom Price walks back comments saying ACA mandate repeal will drive up costs

A day after saying the repeal of the Affordable Care Act (ACA)’s individual mandate would cause costs to rise for enrollees remaining in ACA plans, former HHS Secretary Tom Price, MD, claimed his remarks were taken out of context.

“Repealing the individual mandate was exactly the right thing to do. Forcing Americans to buy something they don’t want undermines individual liberty as well as free markets,” Price said in a statement released through the Job Creators Network, a pro-business group for which he is a healthcare fellow. “The only fair and effective way to bring down healthcare costs is to allow markets to create more choices for consumers and small businesses.”

In a May 1 speech at the World Health Care Congress, Price said the move by Republicans to zero out the penalty for not having health insurance coverage through their 2017 tax cut law was “nibbling at the sides” of the ACA and then clearly stated it would raise costs.

“There are many, and I am one of them, who believe that that actually will harm the pool in the exchange market because you'll likely have individuals who are younger and healthier not participating in that market,” he said. “And, consequently, that drives up the cost for other folks in that market.”

The remarks attracted attention because they contradicted Price’s stances and statements both as a congressman and during his short tenure as HHS Secretary. As he was championing ultimately unsuccessful efforts to fully repeal the ACA, Price told ABC News in July 2017 the mandate “is one of those things that actually is driving up the cost for the American people in terms of coverage.”

Price’s remarks at the conference are in line with predictions from within government and the insurance industry. Before the tax cut law passed, the American Academy of Actuaries warned premiums would rise, the ACA market’s risk pool would worsen and insurers may exit exchanges in fear of taking heavy losses. The Congressional Budget Office predicted the ACA market would be stable without the mandate, but 13 million more people would be uninsured by 2027.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.